Targeted blocking of FXI to prevent thromboinflammation in bacterial sepsis
Official title: Contact Activation and Infection
Funded at Oregon Health & Science University · NIH-11563775 · Data updated 2026-11-12
Aims to see if inhibiting FXI can reduce blood clotting and inflammation during serious bacterial infections like anthrax, to improve outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | September 23, 2020 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $864,107 |
| NIH project number | 2R56AI157037-06A1 |
| Project ID | NIH-11563775 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with systemic bacterial infection or sepsis at risk of thromboinflammation, who could benefit from therapies impacting coagulation and inflammation.
✕Less likely to help
Patients with non-septic infections or bleeding disorders where FXI inhibition is unsafe or ineffective may not benefit.
What this research studies
This project tests whether blocking a blood-clotting protein called FXI can lessen the dangerous clotting and inflammatory responses that occur during severe bacterial infections. The team uses computer simulations, lab experiments, and animal models to study how FXI inhibition might change the course of sepsis. The goal is to find a strategy that could complement antibiotics and reduce organ damage and death from septic shock. If successful, this work could guide future therapies to make sepsis safer for patients.
Why it matters
Potential benefit: If FXI inhibition proves effective, patients with severe bacterial infections or sepsis could have better outcomes with reduced risk of organ failure and death.
How similar studies have gone: Previous studies suggest targeting FXI can reduce thrombosis with potentially lower bleeding risk, supporting this approach as promising but requiring confirmation.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Mccarty, Owen J — Oregon Health & Science University
- Study coordinator: Mccarty, Owen J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.